Deals in Depth: August 2008
August 2008 dealmaking highlights: excluding the $3.1 billion CSL/Talecris takeover, there was a weak showing in M&As across all industries in both the number of transactions done and total dollar value; and CSL's $1.5 billion private placement to support the acquisition was mainly responsible for the 75% showing in PIPE financings.
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.